An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

NCT00373659 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab (Lucentis)

Sponsor

University of Miami